What is the Oncomine™ Comprehensive Assay Plus? It is an advanced targeted Next-Generation Sequencing (NGS) panel that provides Comprehensive Genomic Profiling (CGP). Powered by Ion Torrent™ technology, it analyzes 517 unique genes across key cancer-related biomarkers in a single test, streamlining precision oncology research and personalized medicine.
Comprehensive Biomarker Detection
The Oncomine™ Comprehensive Assay Plus enables detection of a wide range of genomic alterations critical for cancer diagnosis and treatment planning. The assay covers:
- Single Nucleotide Variants (SNVs) & Indels: Small insertions and deletions across 517 genes.
- Copy Number Variations (CNVs): High-precision gene amplifications and deletions.
- Gene Fusions: Structural rearrangements, including ALK, ROS1, RET, and NTRK fusions.
- Microsatellite Instability (MSI): Comprehensive MSI status determination.
- Tumor Mutational Burden (TMB): Accurate assessment of overall mutation load.
- Loss of Heterozygosity (LOH): Detection of allelic imbalance.
Proven Clinical Accuracy
Precision is paramount in genomic profiling. The assay delivers exceptional analytical performance across various variant types:
- 99.26% Positive Percent Agreement (PPA) for SNVs.
- 97.03% Positive Percent Agreement (PPA) for Indels.
- 99.59% Overall accuracy across all tested variant types.
Fast, Automated Workflow on the Genexus™ System
Running on the Genexus™ Integrated Sequencer, the entire NGS workflo, from library preparation to variant reporting, is fully automated. This integration reduces hands-on time to approximately 5 minutes per sample. Results are available in as little as one business day, enabling rapid turnaround times and accelerated clinical decision-making.
Frequently Asked Questions (FAQ)
-
How long does the Oncomine Comprehensive Assay Plus take?
Running on the Genexus system, the assay requires only 5 minutes of hands-on time and delivers comprehensive reports in exactly one business day. -
How many genes are covered in the assay?
The assay analyzes 517 unique genes, simultaneously evaluating SNVs, Indels, CNVs, Fusions, TMB, MSI, and LOH.
Partnering with ANTISEL
“With a strong presence in Greece and abroad, we operate in fields that directly impact the health and well-being of people and societies.”
As a group of companies active in Biotechnology, Medical Technology, Analytical Instruments, and Diagnostic Applications, ANTISEL is dedicated to bringing cutting-edge genomic solutions to the scientific community.